Paul Casabianca

Years Active: 2024-2024
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Paul Casabianca, Marc Massetti, François-Emery Cotte, Romain Moreau, Sarah Kassahun, Prianka Singh, Inkyu Kim, Anne-Françoise Gaudin, Guillaume Piessen, Henri Leleu
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France. PharmacoEconomics - open 8 (5) (2024)
Paul Casabianca, Marc Massetti, François-Emery Cotte, Romain Moreau, Sarah Kassahun, Prianka Singh, Inkyu Kim, Anne-Françoise Gaudin, Guillaume Piessen, Henri Leleu
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France. PharmacoEconomics - open 8 (5) (2024)
Paul Casabianca, Marc Massetti, François-Emery Cotte, Romain Moreau, Sarah Kassahun, Prianka Singh, Inkyu Kim, Anne-Françoise Gaudin, Guillaume Piessen, Henri Leleu
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France. PharmacoEconomics - open (2024)
Paul Casabianca, Marc Massetti, François-Emery Cotte, Romain Moreau, Sarah Kassahun, Prianka Singh, Inkyu Kim, Anne-Françoise Gaudin, Guillaume Piessen, Henri Leleu
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France. PharmacoEconomics - open 8 (5) (2024)

Paul Casabianca.css-eqlu8i{font-size:small;padding-left:4px;}